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CONTEXT AND OBJECTIVE: The proteins p63, 
p-cadherin and CK5 are consistently expressed 
by the basal and myoepithelial cells of the breast, 
although their expression in sporadic and familial 
breast cancer cases has yet to be fully defi ned. 
The aim here was to study the basal immunopro-
fi le of a breast cancer case series using tissue 
microarray technology.
DESIGN AND SETTING: This was a cross-sectional 
study at Universidade Estadual de Campinas, 
Brazil, and the Institute of Pathology and Mo-
lecular Immunology, Porto, Portugal.
METHODS: Immunohistochemistry using the 
antibodies p63, CK5 and p-cadherin, and also 
estrogen receptor (ER) and Human Epidermal 
Receptor Growth Factor 2 (HER2), was per-
formed on 168 samples from a breast cancer 
case series. The criteria for identifying women 
at high risk were based on those of the Breast 
Cancer Linkage Consortium. 
RESULTS: Familial tumors were more frequently 
positive for the p-cadherin (p = 0.0004), p63 
(p < 0.0001) and CK5 (p < 0.0001) than was 
sporadic cancer. Moreover, familial tumors had 
coexpression of the basal biomarkers CK5+/
p63+, grouped two by two (OR = 34.34), while 
absence of coexpression (OR = 0.13) was associ-
ated with the sporadic cancer phenotype. 
CONCLUSION: Familial breast cancer was 
found to be associated with basal biomarkers, 
using tissue microarray technology. Therefore, 
characterization of the familial breast cancer 
phenotype will improve the understanding of 
breast carcinogenesis. 
KEY WORDS: Breast neoplasms. Biological markers. 
Genetic markers. Immunohistochemistry. Inborn 
genetic diseases.  
INTRODUCTION
The understanding of breast biology and 
pathology is currently based on a concept 
of two cell types: glandular or luminal cells 
and myoepithelial cells.1 These cells have 
a common origin, arising from totipotent 
progenitor cells located in a suprabasal com-
partment between the myoepithelium and 
the luminal layer.2 Recent studies on breast 
cancer genetic expression using microarrays 
of complementary DNA (cDNA) have made 
it possible to distinguish two principal classes 
of tumor: one with the characteristics of basal 
cells and the other with the characteristics of 
luminal cells.3-6
The majority of sporadic breast cancer 
cases originate from luminal epithelial cells, 
and this fi nding is supported by morphologi-
cal, biochemical and molecular evidence.4,5,7,8 
A previous study carried out by our group 
showed that it is possible to characterize a 
basal breast cancer phenotype using the fol-
lowing markers: p63, cytokeratin 5 (CK5) and 
p-cadherin (p-cad).9 Essentially, cytokeratins 
5 (CK5), 6 and 14 are recognized as basal 
forms of cytokeratin, whereas cytokeratins 
8, 18 and 19 are expressed by glandular or 
luminal cells.10,11
The protein p63 is a homologous 
nuclear transcription factor of p53 and is 
necessary for breast development, as shown 
in experimental studies with knockout rats. 
The Tp63 gene encodes at least six differ-
ent isoforms, and one of these (ΔNp63) is 
expressed in the basal cell population of the 
epithelium.12 Immunohistochemical studies 
have shown that p63 protein expression 
takes place in the nuclei of normal adult 
epithelial progenitor/basal cells, and that 
the predominant isoform is ΔN-p63α. 
Expression of this protein is lost with dif-
ferentiation of the progenitor cells into 
luminal cells.13,14 
p-cadherin is a glycoprotein that, in 
breast ducts and ductal-terminal units, is 
only expressed by myoepithelial and basal 
cells.15,16 Some studies have shown an associa-
tion between p-cadherin expression in breast 
carcinomas and a myoepithelial embryonic 
and stem-cell-like phenotype.17-19
Thus, p63, p-cad and CK5 proteins are 
consistently expressed by the basal and myoep-
ithelial cells of the breast,10-13,20,21 although the 
expression of these proteins in sporadic and 
familial breast cancer has yet to be fully de-
fi ned. Immunohistochemical profi les in such 
cases have become easier to determine with the 
advent of tissue microarray technology. 
OBJECTIVE 
The objective of this study was to evaluate 
the expression of basal biomarkers such as p63, 
p-cadherin and CK5, as well as estrogen re-
ceptor (ER) and Human Epidermal Receptor 
Growth Factor 2 (HER2), in a series of familial 




Clinical information, pathology reports, 
slides and paraffi n blocks were obtained with 
the informed consent of patients, under 
the guidelines and approval of the Medical 
Research Ethics Committee of the School 
of Medical Sciences, Universidade Estadual 
de Campinas (Unicamp), and the National 
Commission for Research Ethics (Comissão 
Nacional de Ética em Pesquisa, Conep).
Patient selection
168 women with breast carcinoma who 
were undergoing treatment at the Breast 
Cancer Outpatient Clinic of the Women’s 
Comprehensive Healthcare Center (Centro 
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de Atenção Integral à Saúde da Mulher, CA-
ISM/Unicamp) were identifi ed and invited 
to participate in this study. The criteria for 
identifying women at high risk were based on 
those of the Breast Cancer Linkage Consor-
tium,22,23 as follows: early onset (less than 45 
years old) and/or bilaterality; more than three 
cases of breast cancer and more than one case 
of ovarian cancer in the family; more than 
two fi rst-degree relatives involved and cases 
of male breast cancer.
Tissue microarray (TMA) 
construction
The TMA was constructed by acquiring 
2.0 mm biopsy cores from representative 
areas of 168 tumors (TMA builder ab1802, 
Abcam®, Cambridge, United Kingdom).
Eleven TMA blocks (Figures 1A and 1B) 
were constructed, each containing 24 tissue 
cores arranged in a 4 x 6 sector. In each TMA 
block, non-neoplastic breast tissue cores were 
also included as controls. After construction, 
2 µm tissue sections were cut and placed on 
Superfrost® Plus glass slides. One hematoxy-
lin and eosin-stained 4 µm section from each 
block was reviewed to confi rm the presence 
of morphologically representative areas of the 
original lesions. 
Immunohistochemistry
Immunohistochemical staining was 
performed using the streptavidin-biotin-
peroxidase technique (Lab Vision Corpora-
tion, Fremont, California, United States) 
on each set of 11 glass slides comprising the 
TMAs. Antigen retrieval was performed by 
incubating the TMA sections in an antigen 
unmasking solution at pH 6.0 (Vector Labo-
ratories, Inc., Burlingame, California, United 
States), or in ethylenediaminetetracetic acid 
(EDTA), pH 8 (Lab Vision) at 98º C. The 
antigen retrieval time, antibodies, dilutions 
and suppliers are listed in Table 1. After 
washing in phosphate buffer solution (PBS), 
endogenous peroxidase activity was blocked 
by incubating the slides in a 3% hydrogen 
peroxide solution in methanol (Merck, 
Germany). The slides were incubated with 
blocking serum (Lab Vision) for 10 min-
utes and then incubated with the specifi c 
antibody. Immunostaining was performed 
overnight at 4º C (p-cadherin and CK5) or 
for one hour at room temperature (HER2, 
ER, and p63). After washing, the slides were 
incubated with biotinylated secondary anti-
body, followed by streptavidin-conjugated 
peroxidase (Lab Vision). Diaminobenzidine 
was used as a chromogen. The tissues were 
then counterstained with hematoxylin, and 
cover slips were attached using a permanent 
mounting solution (Zymed, San Francisco, 
California, United States).
The immunoreactions were classifi ed 
by estimating the percentage of tumor cells 
showing characteristic staining. In non-neo-
plastic breast tissues, p63 showed nuclear 
positivity in myoepithelial cells. p-cadherin 
presented distinctive membranous and oc-
casionally cytoplasmic immunoreactivity 
in non-neoplastic myoepithelial cells. CK5 
staining was present in the myoepithe-
lial cells of breast lobules and ducts. Two 
pathologists (RD and FS) evaluated the 
immunohistochemical staining. Because 
non-neoplastic mammary secretory cells 
do not express p-cadherin, either membra-
nous or cytoplasmic immunoreactivity was 
considered positive when more than 10% of 
the neoplastic cells expressed this marker.12,24 
Similarly, we adopted the same cutoff value 
for nuclear p63 and ER reactivity.
To evaluate HER2, the percentage of 
cells with membranous staining and the in-
tensity of the staining were assessed. HER2 
was evaluated according to the four-category 
system (0-3+) and was considered positive 
when 3+ was attributed. We compared 
our HER2 results with fl uorescence in situ 
hybridization (FISH) information that had 
previously been obtained. Out of the 73 tu-
mor cases with FISH information available, 
27 were simultaneously positive and 39 were 
simultaneously negative. Only seven tumors 
presented discordant information, of which 
fi ve were HER2-positive and FISH-negative, 
and two were HER2-negative and FISH-
positive. In cases of discordance, the FISH 
results were deemed to prevail.
Statistical analysis
Data entry was carried out in the Excel 
software program (Microsoft) and then the 
data were exported to the StatView statistical 
analysis program, version 5.0 (SAS Institute 
Inc., Cary, North Carolina, United States). 
The relationships between the expression 
patterns of the molecular biomarkers were 
evaluated by constructing contingency tables 
and consequently applying the chi-squared 
test. The associations were considered statisti-
cally signifi cant when p < 0.05.25
RESULTS
TMA validation
To validate the immunohistochemical 
analysis of the TMA, the ER expression for 
the sporadic cancers that was obtained in 
this study was compared with the data in the 
patients’ clinical records. Out of the 118 cases 
studied, 111 were concordant (86 were simul-
taneously positive and 25 were simultaneously 
negative). Only three cases presented discord-
ant information and four could not be inter-
preted. The high percentage of concordance 
(97.4%) justifi ed the subsequent analysis.
B
Table 1. Antibodies used in immunohistochemical study of breast cancer tumors
Biomarker Antibody Clone Dilution Origin
CK5 Mmab XM26 1:80 Neomarkers, USA
p-cadherin Mmab 56 1:50 BDTransduction, USA
p63 Mmab 4A4 1:150 Neomarkers, USA
Erα Rmab SP-1 1:20 Neomarkers, USA
HER2 MMab NCL-L-CB11 1:60 Novocastra, UK
Figure 1A and 1B. Construction of tissue 
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Immunohistochemical profi le 
of familial and sporadic 
breast cancer cases
Immunohistochemical analysis was con-
ducted on each group of 11 slides that made 
up the TMAs for p63, p-cadherin, CK5, ER 
and HER2. The results are presented in Table 
2 and Figures 2 and 3. 
The familial breast cancer phenotype was 
more frequently positive for the basal biomar-
kers p-cadherin (p = 0.0004), p63 (p < 0.0001) 
and CK5 (p < 0.0001) than was the sporadic 
cancer phenotype. To evaluate the association 
between coexpression of basal biomarkers and 
the type of cancer, whether familial or sporadic 
breast cancer, the tumors were divided into 
six groups combining coexpression or lack 
of coexpression of the p63, p-cadherin and 
CK5 proteins. The presence of coexpression 
of the basal biomarkers CK5+/p63+ (odds 
ratio, OR = 34.34), grouped two by two, 
was associated with the familial breast cancer 
phenotype, while the absence of coexpression 
of the basal biomarkers CK5-/p63- and CK5-
/p-cadherin- (OR = 0.13) was associated with 
the sporadic cancer phenotype. All the cases of 
basal phenotype (ER-/HER2-) were familial 
breast cancers (Table 3). 
DISCUSSION
The objective of this study was to evalu-
ate the expression of basal biomarkers such as 
p63, p-cadherin and CK5 in a series of familial 
breast cancer cases, using TMA. Familial breast 
cancer was characterized by the expression of 
these biomarkers. On the other hand, basal 
biomarker expression was signifi cantly lower 
in cases of the sporadic cancer phenotype.
The studies with cDNA microarrays 
carried out by Perou et al.3 and de Sorlie 
et al.6 involved more than 8,000 genes 
from which different phenotypes of breast 
cancer were characterized. This scenario 
points towards the existence of strong gene 
interaction in the carcinogenic process, al-
though this technology is not yet applicable 
in clinical practice. It is necessary, however, 
to identify markers that represent these 
genetic spectrums, using techniques that 
are currently available and are applicable 
in clinical practice.
This study therefore makes a contribution 
in the sense that it shows that the proteins 
associated with the basal cell phenotype are 
much more frequently present in familial 
breast cancer phenotype, and that they are 
much more frequently absent in the cancers 
that are considered sporadic and which follow 
the luminal pattern.
Table 2. Results from immunohistochemical staining on tissue microarray of breast 
cancer tumors





p-cadherin 166 121 (73%) 45 (27%)
CK5 149 33 (21%) 116 (78%)
p63 154 31 (20%) 123 (78%)
ER 166 121 (73%) 45 (27%)
HER2 162 56 (34%) 106 (65%)
Table 3. Immunohistochemical profi les of familial (FH+) and sporadic (FH-) breast cancer 








Only p63+ 19 (40%) 12 (11%) 5.37 (2.16-13.53) < 0.0001
Only CK5+ 23 (49%) 10 (9.8) 8.42 (3.43-23.15) < 0.0001
Only p-cad+ 25 (51%) 21 (22%) 3.72 (1.67-8.36) 0.0004
p-cad+ and p63+ 12 (25%) 3 (3%) 9.89 (2.39-47.23) < 0.0001
p-cad- and p63- 15 (33%) 63 (69%) 0.22 (0.10-0.51) < 0.0001
CK5+ and p63+ 12 (26%) 1 (1%) 34.2 (4.33-731.14) < 0.0001
CK5- and p63- 17 (36%) 80 (80%) 0.13 (0.06-0.31) < 0.0001
p-cad+ and CK5+ 14 (30%) 6 (7%) 6.46 (2.07-20.9) 0.0003
p-cad- and CK5- 14 (29%) 68 (76%) 0.13 (0.05-0.30) < 0.0001
Only ER- 19 (38%) 26 (22%) 0.45 (0.21-0.99) 0.03
Only HER2 negative 37 (77%) 42 (42%) 0.22 (0.09-0.52) < 0.0001
Total number of cases (n) 50 118
FH (+): familial history positive; FH (-): familial history negative. 
Positive cases were those that confi rmed the profi le under analysis. All others were considered negative.
Figure 2. Sporadic breast carcinoma profi le. A) ER positivity; B) HER2 positivity.
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The estrogens that bind to the ER located 
in the cell nucleus, and the growth factors that 
bind to the HER2 protein located in the cell 
membrane represent two different routes for 
cell proliferation stimuli originating outside the 
cell. Therefore, it is possible to hypothesize that, 
when these lesions do not express ER or HER2 
protein, the stimuli for cell proliferation would 
be determined by factors inside the cell or at least 
would be less dependent on external stimuli. 
Thus, the development of ductal carcinoma in 
situ (DCIS) would be more heavily dependent 
on external factors modulated by ER and HER2, 
while the progression to invasive cancer would 
be less dependent on this route, possibly because 
of the progressive accumulation of genetic altera-
tions that occur in the malignant cells.26-29
Perou et al.3 characterized basal-subtype 
breast cancers as ER and HER2-negative. 
Therefore, these would be the cancers in which 
cell proliferation would depend less on external 
factors. Several studies have shown that women 
with the breast cancer 1 (BRCA1) gene mutation 
present breast cancer with a genetic expression 
pattern that is compatible with the basal sub-
type.5,30-33 However, the multistage process of 
carcinogenesis in the breast epithelium of women 
with genetic abnormalities who are highly 
susceptible to carcinogenesis would not depend 
on ER or HER2 protein expression, since the 
stimuli required for cell proliferation would be 
determined by the abnormalities present in the 
cell genome. Obviously, this explanation does 
not exclude the possibility that these cells may 
also have ER and HER2 protein expression.
Foulkes and colleagues26,32 studied this 
phenotype and found that around 40% of basal 
cancers presented a mutation in the BRCA1 
gene, thus suggesting that this gene has a regula-
tory function in the progenitor cells of the breast 
and that it promotes the orderly transition of 
the cells to the glandular epithelial phenotype. 
Mutation of this gene would lead to interruption 
of the differentiation process, and the cells would 
remain stagnant in a primitive basal phenotype 
with no proliferation control.
The results from our study are in agreement 
with this theory on carcinogenesis, since they 
show that the familial breast cancer phenotype 
is more frequently ER (-) and HER2 protein (-) 
than are sporadic cancers. Moreover, the p63, 
p-cadherin and CK5 biomarkers showed that fa-
milial breast cancer cases more frequently present 
expressions compatible with the basal pheno-
type. As a rule, the sporadic cancer phenotype 
presents lower frequency of expression of these 
biomarkers. The remainder of our results are in 
full accordance with those in the literature.
CONCLUSIONS
This familial cancer case series was found 
to be more frequently positive for the basal 
biomarkers p-cadherin, p63 and CK5, using 
tissue microarray technology. The scientifi c 
value of TMA was demonstrated through this 
study, even though the number of specimens 
was low. Many of the phenotypic features of 
familial cancer tumors might also be found 
in putative breast stem cells. Therefore, 
characterization of the familiar breast cancer 
phenotype will improve the understanding of 
breast carcinogenesis.
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RESUMO
Tissue microarrays para testar as proteínas basais no câncer de mama familiar
CONTEXTO E OBJETIVO: As proteínas p63, p-cad e CK 5 são expressas em células basais/mioepiteliais 
da mama. Entretanto a expressão dessas proteínas no câncer esporádico e familiar ainda não é bem 
conhecida. O objetivo do estudo foi estudar essas proteínas no câncer de mama, utilizando a técnica de 
tissue microarray, assim como ER e HER2.
TIPO DE ESTUDO E LOCAL: Estudo transversal, realizado no Centro de Atenção Integral à Saúde da Mulher, 
Universidade Estadual de Campinas, Brasil, e no Instituto de Patologia e Imunologia Molecular da Univer-
sidade do Porto, Portugal.
MÉTODOS: O estudo analisou a expressão das proteínas p63, CK 5, p-cad, ER e HER2 numa série de 
168 casos de câncer de mama. Os critérios utilizados para identifi car as mulheres com alto risco foram 
os do Breast Cancer Linkage Consortium.
RESULTADOS: A série de câncer familiar foi freqüentemente mais positiva para as proteínas basais 
p-cadherin (p = 0,0004), p63 (p < 0,0001) e CK 5 (p < 0,0001) que o câncer esporádico. A presença 
da co-expressão das proteínas basais CK 5+/p63+, agrupados dois a dois, foi associada com o fenótipo 
do câncer familiar (odds ratio, OR = 34,34), enquanto que sua ausência foi com o câncer esporádico 
(OR = 0,13).
CONCLUSÕES: O câncer da mama familiar está associado aos marcadores de células basais proteínas 
p63, p-cad e CK 5, utilizando-se a técnica de tissue microarray. Por fi m, parece legítima a interpretação 
destes resultados como mais uma evidência que suporta a hipótese da existência de células precursoras 
do câncer familiar da mama. O conhecimento dos perfi s de expressão destas células, bem como das vias 
de sinalização envolvidas, benefi ciarão o entendimento da carcinogênese mamária.
PALAVRAS-CHAVE: Câncer da mama. Marcadores biológicos. Marcadores genéticos. Imunohistoquímica. 
Doenças genéticas inatas.
